ライフサイエンスコーパス: arginine methyl ester

1 ith a nonselective inhibitor (Nomega-nitro-L-arginine methyl ester).

2 ynthase (NOS) inhibitor L-NAME (N(D)-nitro-L-arginine methyl ester).

3 nitric oxide synthase with N(omega) -nitro-l-arginine methyl ester.

4 oxide synthase (eNOS) inhibitor N(G)-nitro-L-arginine methyl ester.

5 e nitric oxide synthase inhibitor NG-nitro-l-arginine methyl ester.

6 d by using a specific NOS inhibitor, nitro-l-arginine methyl ester.

7 synthesis was inhibited by N(omega)-nitro-l-arginine methyl ester.

8 ular L-arginine and was inhibited by L-nitro-arginine methyl ester.

9 was not significantly affected by N-nitro-L-arginine methyl ester.

10 ar endothelium with 50 micromol/L NG-nitro-L-arginine methyl ester.

11 y altered in response to glucose and L-nitro-arginine methyl ester.

12 t was abrogated by administration of nitro-l-arginine methyl ester.

13 was reduced by tetrodotoxin or N(G)-nitro-l-arginine methyl ester.

14 nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester.

15 d absence of the eNOS inhibitor N(G)-nitro-L-arginine methyl ester.

16 henyltheophylline in the presence of L-nitro-arginine-methyl ester.

17 cts inhibited by the NOS inhibitor N-nitro-L-arginine-methyl ester.

18 in) followed by a 10-min infusion of L-nitro-arginine-methyl ester (0.5 mg/kg x min).

19 1) for 28 days) or treatment with NG-nitro-L-arginine methyl ester (1 mg/mL in drinking water for 28

20 whereas its inactive enantiomer N(w)-nitro-D-arginine methyl ester (1 mM) resulted in microglial accu

21 pplication of the NOS inhibitor N(w)-nitro-L-arginine methyl ester (1 mM) significantly reduced micro

22 er inhibition of NO synthase with NG-nitro-L-arginine methyl ester (1 to 2 mg/kg IV) had raised the p

23 nitric oxide synthase inhibitors Ng-nitro-L-arginine-methyl ester (1.5 mmol/L) and aminoguanidine (1

24 Nomega-Nitro-L-arginine methyl ester 10(-4) mol/L modestly impaired FID

25 transcription inhibitor; or N(omega)-nitro-L-arginine methyl ester (10(-4) mol/L), an inhibitor of NO

26 ed after NO synthase blockade with N-nitro-L-arginine methyl ester (10(-4) mol/L; all P<0.05).

27 N(G)-nitro-l-arginine methyl ester (100 mumol/L) or a protease-activa

28 tive NO* synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (100-800 nmol) as well as by the s

29 L-Nitro-arginine methyl ester (15 mg kg(-1)), an inhibitor of en

30 blockade of NO production with N(G)-nitro-L-arginine-methyl ester (2 micromol; delivered ICV, 30 min

31 The NO synthase inhibitor N-nitro-L-arginine methyl ester (200 microM) reversed this oxidant

32 events were blocked by L-NAME (N(G)-nitro-L-arginine methyl ester, 3-30 mg/kg), a nitric oxide synth

33 nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester (30 mg/kg iv) was administered.

34 s blocked by the NOS inhibitors N(G)-nitro-L-arginine methyl ester (30 microm) or N(G)-monomethyl-L-a

35 nonselective NOS inhibitor (N(omega)-nitro-L-arginine methyl ester; 30 mg/kg), a soluble guanylyl cyc

36 ic oxide synthase inhibitor (N-omega-nitro-L-arginine methyl ester, 50 mg/kg/day) or peroxynitrite sc

37 synthase (NOS) inhibition with N(W)-nitro-L-arginine methyl ester (60 mg/kg), vasoconstriction induc

38 Moreover, l-NAME (N(omega)-nitro-l-arginine-methyl ester), a specific inhibitor of nitric o

39 Nomega-nitro-L-arginine methyl ester, a nonspecific inhibitor of endoge

40 stically amplified by co-addition of tosyl-l-arginine methyl ester, a small molecule that blocks the

41 N(omega)-nitro-l-arginine methyl ester abolished the systemic but not the

42 rings, which was unaffected by L(G)-nitro-l-arginine methyl ester addition and inhibited by the guan

43 creased significantly more than with L-nitro-arginine-methyl ester alone, but there were no further i

44 The inhibition of eNOS with N-omega-nitro-L-arginine methyl ester also potently reduced retinal leuk

45 eatment with the eNOS inhibitor N(G)-nitro-L-arginine methyl ester also reduced endothelial cell migr

46 s 7-nitroindazole (7-NI) and N-omega-nitro-L-arginine methyl ester also reduced NMDA toxicity.

47 antly inhibited in the presence of N-nitro-L-arginine methyl ester (an inhibitor of NOS) and wortmann

48 kinase (ERK) inhibitor, and N(omega)-nitro-L-arginine methyl ester, an antagonist of nitric oxide syn

49 he effects of nicardipine; N omega-I-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synt

50 ebroventricular infusion of N(omega)-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synt

51 a)) channels, respectively, and N(G)-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synt

52 horylation, which was abolished by N-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synt

53 nthase expression; in contrast, N(G)-nitro-L-arginine methyl ester, an inhibitor of NO synthase, inhi

54 Pretreatment of rats with L-N(G)-nitro arginine methyl ester, an inhibitor of NO synthase, prev

55 f NFkappaB into the nucleus, 3) N(G)-nitro-l-arginine methyl ester, an inhibitor of NO synthesis, abo

56 The administration of NG-nitro-L-arginine methyl ester, an inhibitor of NOS activity, inc

57 expression was abrogated by N(omega)-nitro-l-arginine methyl ester, an inhibitor of NOS.

58 N(omega)-Nitro-L-arginine methyl ester and 1H-[1,2,4]-oxadiazolo-[4,3-a]-

59 learance, whereas infusion of Nomega-nitro-L-arginine methyl ester and a high dose of aminoguanidine

60 e, because it was not inhibited by N-nitro-l-arginine methyl ester and also occurred in vascular smoo

61 The NOS inhibitor N(G)-nitro-l-arginine methyl ester and genistein, wortmannin, or NF-k

62 ic mice during coadministration of N-nitro-l-arginine methyl ester and indomethacin.

63 acid and by NO synthase inhibitor NG-nitro-L-arginine methyl ester and NG-monomethyl-L-arginine.

64 nd inhibition of NO synthase by N(G)-nitro-L-arginine methyl ester and of soluble guanylyl cyclase by

65 nd NOS1-specific NOS inhibitors N(G)-nitro-l-arginine methyl ester and S-methyl-l-thiocitrulline, res

66 ic oxide synthase inhibitors N-omega-nitro-L-arginine methyl ester and S-methyl-thiocitrulline.

67 r treatment with a combination of NG-nitro-l-arginine methyl ester and sodium nitroprusside.

68 treatment with a combination of N(G)-nitro-L-arginine methyl ester and sodium nitroprusside.

69 nitric oxide synthase inhibitor N(G)-nitro-l-arginine methyl ester and the neuronal blocker tetrodoto

70 ith the nonspecific NOS inhibitor NG-nitro-L-arginine methyl ester and the NOS1-specific inhibitor 7-

71 on by the NO synthase inhibitor N(G)-nitro-l-arginine methyl ester and the superoxide dismutase mimic

72 stitutive NO synthase inhibitor N(G)-nitro-l-arginine methyl ester and unresponsive to stimulation by

73 of NKCC1, whereas the antioxidants N-nitro-l-arginine methyl ester and uric acid all significantly di

74 bility, and pretreatment with both N-nitro-L-arginine methyl ester and wortmannin inhibited the Tat-i

75 In RAW cells, Ng-nitro-L-arginine-methyl ester and AG block IFNgamma/LPS-activate

76 oxide (NO) synthase (by L-NAME; N(G)-nitro-L-arginine methyl ester) and blockade of soluble guanylyl

77 iated arginine and singly hydrated lithiated arginine methyl ester are different and contain spectral

78 d arginine, sodiated arginine, and lithiated arginine methyl ester are investigated using infrared ac

79 d alkali metal cationized arginine (Arg) and arginine methyl ester (ArgOMe) are investigated with inf

80 NOS inhibitor N(G)-nitro-L-arginine methyl ester attenuated the endothelial barrier

81 The NOS inhibitor, N-nitro-L-arginine methyl ester, attenuated the microvascular leak

82 ac1 inhibitor NSC 23766 but not an N-nitro-L-arginine-methyl ester-attenuated ESR O2*- signal at 30 m

83 tion of nitric oxide synthase with N-nitro-L-arginine methyl ester, but not with the inactive D-isome

84 se appeared to be unaffected by N(G)-nitro-L-arginine methyl ester, but the second rise was reduced.

85 In the presence of K(G)-nitro-L-arginine methyl ester, ceramide produced no further inhi

86 tric oxide synthase inhibitor Nomega-nitro-L-arginine methyl ester completely abrogated the increase

87 letely by superoxide dismutase and N-nitro-L-arginine methyl ester, consistent with the hypothesis th

88 ive effect of the NOS inhibitor N(G)-nitro-L-arginine methyl ester could be attributed to dramaticall

89 r the glycine (CyGly), arginine (CyArg), and arginine methyl ester (CyArgOMe) derivatives.

90 r (L-NAME) or its inactive isomer NW-nitro-D-arginine methyl ester (D-NAME) and were trained on a neg

91 hyl ester (L-NAME; 8 mg/kg), or N(G)-nitro-D-arginine methyl ester (D-NAME; 8 mg/kg).

92 nimals received saline, L-NAME or NG-nitro-D-arginine-methyl ester (D-NAME; 8 mg/kg) during the pulmo

93 The NOS inhibitors, N-nitro-L-arginine methyl ester, dexamethasone and indomethacin po

94 nd inhibition of NOS activity with N-nitro-L-arginine methyl ester did not block the beneficial effec

95 nitric oxide synthesis inhibitor, NG-nitro-l-arginine methyl ester, did not reverse the inhibitory ef

96 e non-isoform-specific NOS inhibitor L-nitro-arginine methyl ester during 3 weeks of remobilization h

97 ion of nitric oxide synthase by N(w)-nitro-L-arginine methyl ester eliminated antiadrenergic effects

98 Group 2 similarly received L-nitro-arginine-methyl ester followed by 8-sulfophenyltheophyll

99 Aromatic templates also transported N-acetyl arginine methyl ester from water to 1-octanol.

100 e vascular bed of the cat, N omega-I-nitro-L-arginine methyl ester, glibenclamide, and meclofenamate

101 xin or BAPTA-AM, but not by N(omega)-nitro-L-arginine methyl ester, glipizide, indomethacin or 17-oct

102 more, the NO synthase inhibitor N(G)-nitro-L-arginine methyl ester had no effect on sperm-induced Ca(

103 ated with ceramide, whereas N(omega)-nitro-l-arginine methyl ester had no effect.

104 oxide (NO) synthase inhibitors N(G)-nitric-L-arginine methyl ester HCl (L-NAME) or N(G)-nitro-L-argin

105 d with NO synthase inhibitors (N(G)-Nitric-L-arginine methyl ester HCl (L-NAME), N(G)-Nitro-L-arginin

106 with the NO synthase inhibitor N(G)-nitric-L-arginine methyl ester HCl (L-NAME), the NO donors were s

107 were quantified in wild-type, Nomega-nitro-L-arginine methyl ester HCl salt (L-NAME)-treated, nNOS(-/

108 N(omega)-Nitro-L-arginine methyl ester, HOE-140, and dichloroisocoumarin

109 tric oxide synthase inhibitor Nomega-Nitro-L-arginine methyl ester hydrochloride (L-NAME) afforded pa

110 iting NO synthase activity with N(G)-nitro-L-arginine methyl ester hydrochloride (L-NAME) blocked TG-

111 ercentage decrease in response to NG-Nitro-L-arginine methyl ester hydrochloride (L-NAME) infusion.

112 oronary VEGF165 0.25 microg/kg/min + nitro-L-arginine methyl ester hydrochloride (L-NAME) or 5) rapid

113 s with the NO synthase inhibitors NG-nitro-L-arginine methyl ester hydrochloride (L-NAME) or NG-monom

114 he broad-spectrum NOS inhibitor N(g)-nitro-L-arginine methyl ester hydrochloride (L-NAME) via their d

115 dministration of the NOS inhibitor N-nitro-L-arginine methyl ester hydrochloride (L-NAME), including

116 ive challenges using either N(omega)-nitro-L-arginine methyl ester hydrochloride (L-NAME)/high salt o

117 Ringer's (control); (2) 20 mm Nomega-nitro-l-arginine methyl ester hydrochloride (non-selective NOS i

118 1400W had no effect, whereas Nomega-nitro-l-arginine methyl ester hydrochloride caused a partial red

119 Incubation of Nomega-nitro-l-arginine methyl ester hydrochloride or 1400W (a nonselec

120 tric oxide synthesis antagonist N(G)-nitro-L-arginine methyl ester hydrochloride or by hemoglobin but

121 production, which was inhibited by N-nitro-l-arginine methyl ester hydrochloride, indicating uncoupli

122 of DTT and the NO inhibitor N(omega)-nitro-L-arginine methyl ester hydrochloride, the ability of CO t

123 (NO) synthesis with L-NAME (N(omega)-nitro-L-arginine methyl ester hydrochloride; 5 mg/kg; i.v.).

124 nd U(cGMP) were suppressed by Nomega-nitro-L-arginine methyl ester in SOD-Tg-db/db but not in NTg-db/

125 th the competitive NOS inhibitor, NG-nitro-l-arginine methyl ester, in cells grown in l-arginine rest

126 form of nitric oxide synthase with N-nitro-L-arginine methyl ester increased DOX-induced mortality.

127 hydro-6-methyl-4H-1,3-thiazine and N-nitro-L-arginine methyl ester) increased RSV titers in the lungs

128 ereas the NO synthase inhibitor N(G)-nitro-L-arginine methyl ester increases ceramide-induced vWF rel

129 vascular resistances increased with L-nitro-arginine-methyl ester infusions, and 8-sulfophenyltheoph

130 availability and reduced basal and N-nitro-l-arginine methyl ester-inhibitable O(2)(.-) in internal m

131 d eNOS uncoupling, as assessed by NG-nitro-l-arginine methyl ester-inhibitable superoxide production,

132 sociated with reduced total and N(G)-nitro-L-arginine methyl ester-inhibitable superoxide, suggesting

133 N(w)-nitro-L-arginine methyl ester, inhibitor of NO synthase, attenua

134 N(G)-nitro-L-arginine methyl ester inhibits the effect of isoproteren

135 ally, blockade of eNOS with N(omega)-nitro-L-arginine methyl ester ( L-NAME) abolished the inhibitory

136 ase material to examine the feasibility of L-Arginine methyl ester (L-AME) functionalized material fo

137 attenuated after NOS blockade with N-nitro-L-arginine methyl ester (L-NAME) (-2+/-5%, -3+/-2%, and -6

138 Addition of the NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) (1 mg/ml) to the drinking

139 Pretreatment with N(omega)-nitro-l-arginine methyl ester (l-NAME) (10(-3) mol/L), propranol

140 (1 micromol/L) with or without N(G)-nitro-L-arginine methyl ester (L-NAME) (100 micromol/L), or 5-hy

141 as unaffected by 100 microM N(omega)-nitro-L-arginine methyl ester (L-NAME) (68 +/- 4 vs. 66 +/- 3% i

142 ; 4) L-arginine before IR; and 5) Nw-Nitro-L-arginine methyl ester (L-NAME) + IPC before IR.

143 itric oxide synthase (NOS) with N(G)-nitro-L-arginine methyl ester (L-NAME) accelerates the 'phase II

144 m baseline, nine animals received NG-nitro-L-arginine methyl ester (L-NAME) at 15 mg/kg to restore MA

145 nitric oxide synthase inhibitor N(w)-nitro-L-arginine methyl ester (L-NAME) before aerosol challenge

146 hibition of NO synthesis with Nomega-nitro-L-arginine methyl ester (L-NAME) blocked the increase in R

147 NG-nitro-L-arginine methyl ester (L-NAME) constricted and indometha

148 inhibitor L-N-iminoethyl lysine or N-nitro-L-arginine methyl ester (L-NAME) decreased the elevated pl

149 ed with the NO synthase inhibitor NG-nitro-l-arginine methyl ester (L-NAME) for 14 days plus Ang II d

150 lective NO synthase inhibitor Nomega-nitro-L-arginine methyl ester (L-NAME) for 30 minutes, followed

151 Infusion of N(G)-nitro-L-arginine methyl ester (L-NAME) for 5 min to inhibit NOS

152 eries was coated with 1 mmol/L of NG-nitro-L-arginine methyl ester (L-NAME) in 22% (wt/vol) Pluronic

153 oxide synthase (NOS) inhibitor N(6)-nitro-L-arginine methyl ester (L-NAME) in drinking water (NLN, I

154 the NO synthase (NOS) inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) increased sorbitol accumu

155 In Site B, NG-nitro-L-arginine methyl ester (L-NAME) infusion during hyperther

156 sely, blockade of NOS using N(omega)-nitro-l-arginine methyl ester (l-NAME) inhibited l-arginine tran

157 of NO synthase inhibition with N(G)-nitro-L-arginine methyl ester (L-NAME) on the magnitude of the r

158 hours with 3 mM ATP or 2 mM N(omega)-nitro-L-arginine methyl ester (L-NAME) or 50 microM Reactive blu

159 e nitric oxide synthase inhibitor NW-nitro-L-arginine methyl ester (L-NAME) or its inactive isomer NW

160 pplication of the NOS inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) or postsynaptic co-inject

161 Molsidomine or NG-nitro-L-arginine methyl ester (L-NAME) or saline were applied da

162 e nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) or the ATP-sensitive mito

163 e report in this article that L-N(G)-nitro-L-arginine methyl ester (L-NAME) pretreatment blocked, whe

164 n of nitric oxide synthase with N(G)-nitro-L-arginine methyl ester (L-NAME) reduced maximal dilation

165 The NO synthase inhibitor N(G)-nitro-l-arginine methyl ester (L-NAME) significantly (P < 0.001)

166 solution infused in one probe and N-nitro-L-arginine methyl ester (L-NAME) through the second.

167 ted by either high glucose or Nomega-nitro-l-arginine methyl ester (L-NAME) treatment.

168 L-arginine or Nomega-nitro-L-arginine methyl ester (L-NAME) was administered to stimu

169 ic oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester (L-NAME) was much greater in LPS-t

170 ediated by nitric oxide (NO), Nomega-nitro-l-arginine methyl ester (l-NAME) was used.

171 oxide synthase (NOS) inhibitor N (G)-nitro-L-arginine methyl ester (L-NAME) worsened LV contractility

172 on of nitric oxide synthase (NOS) by nitro-L-arginine methyl ester (L-NAME) would alleviate the inhib

173 ol 1 (n = 10): (1) Control, (2) N(G)-nitro-l-arginine methyl ester (l-NAME), (3) a KCa channel inhibi

174 otocol: (1) ketorolac (Keto), (2) NG-nitro-l-arginine methyl ester (L-NAME), (3) Keto + l-NAME (Combo

175 s during steady state exercise (N(G)-nitro-L-arginine methyl ester (L-NAME), 25 mg over 5 min to inhi

176 sponse curves to acetylcholine, N(G)-nitro-L-arginine methyl ester (L-NAME), 8-bromo-cyclic 3',5'-gua

177 This activation was inhibited using l-nitro arginine methyl ester (L-NAME), a competitive inhibitor

178 rs was reduced in the presence of NG-nitro-L-arginine methyl ester (L-NAME), a general inhibitor of N

179 paw to block CGRP responses; N-omega-nitro-l-arginine methyl ester (L-NAME), a nonselective nitric-ox

180 N(w)-Nitro-l-arginine methyl ester (l-NAME), a nonspecific inhibitor

181 stration of either 100 mg/kg of N(G)-nitro-L-arginine methyl ester (L-NAME), a nonspecific NOS inhibi

182 n the absence or presence of N-Omega-nitro-L-arginine methyl ester (L-NAME), a specific NOS inhibitor

183 ncreased in the presence of N(omega)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric o

184 Chronic administration of Nomega-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric o

185 N(G)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO synth

186 Treatment with N(G)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO synth

187 lished by application of either N(G)-nitro-l-arginine methyl ester (l-NAME), an inhibitor of NO synth

188 N(omega)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NOS, sig

189 N-nitro-l-arginine methyl ester (L-NAME), an NO synthase inhibitor

190 nitric oxide synthase (NOS) inhibitor N(G)-L-arginine methyl ester (L-NAME), and compared its effects

191 by 7-nitro-indazole (7-NI) or N (G)-nitro-L-arginine methyl ester (L-NAME), completely prevented het

192 a nitric oxide synthase inhibitor, N-nitro-L-arginine methyl ester (L-NAME), on morphine hyperthermia

193 ing an inhibitor of nitric oxide, NG-nitro-L-arginine methyl ester (L-NAME), or a corresponding vehic

194 oxide synthase (NOS) inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME), or by bilateral vagotomy

195 nine, nonspecific NOS inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME), or iNOS selective inhibi

196 ected daily with either saline, N(G)-L-nitro-arginine methyl ester (L-NAME), or N-acetylcysteine for

197 d by a continuous infusion of Nomega-nitro-L-arginine methyl ester (L-NAME), or saline vehicle as con

198 ted, whereas the NOS inhibitor, N(G)-nitro-l-arginine methyl ester (L-NAME), potentiated LT release i

199 c oxide (NO) synthase inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME), the guanylyl cyclase inh

200 nhibition in cancer cells using N(G)-nitro-l-arginine methyl ester (l-NAME), we demonstrate that pati

201 Chronic N(G)-nitro-L-arginine methyl ester (L-NAME), which inhibits nitric ox

202 However, pretreatment of VEC with nitro-L-arginine methyl ester (L-NAME), while inhibiting the rel

203 hieved via systemic infusion of N(G)-nitro-l-arginine methyl ester (l-NAME), would reduce the gas exc

204 In N(G)-nitro-L-arginine methyl ester (L-NAME)- and L-NAME+nifedipine-tr

205 times more superoxide by an N(omega)-nitro-L-arginine methyl ester (L-NAME)-inhibitable mechanism tha

206 In wild-type, N-nitro-L-arginine methyl ester (L-NAME)-treated (with 1 mg/mL in

207 sed in isolated arterioles from N(G)-nitro-L-arginine methyl ester (L-NAME)-treated male and ovariect

208 onectomy but not by atropine or N(G)-nitro-l-arginine methyl ester (L-NAME).

209 se effects, mice were treated with N-nitro-L-arginine methyl ester (L-NAME).

210 the constitutive NOS inhibitor N(G)-nitro-l-arginine methyl ester (L-NAME).

211 e nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME).

212 roduced by systemic infusion of N(G)-nitro-L-arginine methyl ester (L-NAME).

213 long-term NOS inhibition by N(omega)-nitro-L-arginine methyl ester (L-NAME).

214 s of the NO synthase (NOS) inhibitor nitro-L-arginine methyl ester (L-NAME).

215 ion of nitric oxide synthesis with N-nitro-L-arginine methyl ester (L-NAME).

216 ficantly in the presence of N(omega)-nitro-L-arginine methyl ester (L-NAME).

217 ith the NO synthase inhibitor Nomega-nitro-L-arginine methyl ester (L-NAME).

218 ed NOS small molecule inhibitor N(G)-nitro-L-arginine methyl ester (l-NAME).

219 d by systemic pretreatment with L-N(G)-nitro arginine methyl ester (L-NAME).

220 vented by the eNOS inhibitor, Nomega-Nitro-L-arginine methyl ester (L-NAME).

221 nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME).

222 a nonselective NOS inhibitor [Nomega-nitro-L-arginine methyl ester (L-NAME)], or scavenging NO with a

223 ented by inhibition of NOS with N(G)-nitro-L-arginine methyl ester (L-NAME, 1 mM).

224 as tested by using the NOS inhibitor nitro-L-arginine methyl ester (L-NAME, 1 mmol/liter) in the pres

225 c oxide synthase (NOS) inhibitor, l-nitro(G)-arginine methyl ester (l-NAME, 1.5 mM), but was not affe

226 the nonspecific NOS inhibitor Nomega-nitro-L-arginine methyl ester (L-NAME, 10 mg/kg) in normal and s

227 The addition of N(G)-nitro-L-arginine methyl ester (L-NAME, 10(-5) mM), an inhibitor

228 e presence of the NOS inhibitor N(G)-nitro-L-arginine methyl ester (l-NAME, 10(-5) mol l(-1)), the ar

229 he nitric oxide (NO) inhibitor N (G)-nitro-L-arginine methyl ester (L-NAME, 100 mg x kg(-1)) and the

230 hibiting NO synthase (NOS) with N(G)-nitro-L-arginine methyl ester (L-NAME, 250 microg/5 microl of ar

231 NG-nitro-L-arginine methyl ester (L-NAME, 300 microM), an inhibitor

232 ic oxide synthase inhibitor, N-omega-nitro-L-arginine methyl ester (L-NAME, 3x10(-4) mol/l), and sele

233 nistration of the NOS inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME, 50 mg/kg/day) on energy i

234 f saline, GLP-2, and GLP-2 plus N(G)-Nitro-L-arginine methyl ester (L-NAME, 50 micromol x kg(-1) x ho

235 peroxide dismutase-mimetic), N-omega-nitro-L-arginine methyl ester (L-NAME, a nitric oxide synthase i

236 The NG-nitro-L-arginine methyl ester (L-NAME, a NOS inhibitor), increas

237 Microinjection of L-nitro-arginine methyl ester (L-NAME, an NO synthesis inhibitor

238 xamethonium (20 mg kg(-1)) and N (G)-nitro-L-arginine methyl ester (L-NAME; 10 mg kg(-1)), a nitric o

239 months with the NOS inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME; 10 mg/kg per day in drink

240 Treatment with Nomega-nitro-L-arginine methyl ester (L-NAME; 10(-4) mol/L), an NO synt

241 Inhibition of eNOS with N(G)-nitro-l-arginine methyl ester (l-NAME; 10(-6) M) completely inhi

242 argininel-NA; 100 microM) or N omega-nitro-L-arginine methyl ester (L-NAME; 100 microM) applied to th

243 cted instances, the NO synthase inhibitor, L-arginine methyl ester (L-NAME; 100 microM), or the NO do

244 icular (i.c.v.) administration of NG-nitro-l-arginine methyl ester (L-NAME; 150 microg/5 microl) to c

245 oxide synthesis (NOS) inhibitor, NG-nitro-L-arginine methyl ester (L-NAME; 25 micromol/kg, i.v.) in

246 lial nitric oxide synthase with N(G)-nitro-L-arginine methyl ester (L-NAME; 300 microm) eliminated th

247 n of nitric oxide synthase with N(G)-nitro-L-arginine methyl ester (L-NAME; 300 microM).

248 s infusion of the NOS inhibitor N(G)-nitro-l-arginine methyl ester (l-NAME; 4 mg kg(1)), and for 120

249 intraperitoneally with saline, N(G)-nitro-L-arginine methyl ester (L-NAME; 8 mg/kg), or N(G)-nitro-D

250 ncomitant administration of LPS + NG-nitro-L-arginine methyl ester (L-NAME; an NO synthesis inhibitor

251 the NOS inhibitors ADMA or N(omega)-nitro-L-arginine methyl ester (L-NAME; each 250 micromol x kg(-1

252 hyl-L-arginine (L-NMMA; n = 6) or NG-nitro-L-arginine methyl ester (L-NAME; n = 8).

253 OS, L-NG-monomethyl arginine (L-NMMA), and L-arginine-methyl ester (L-NAME) had little or no effect o

254 ith incubation of NOS inhibitor N(G)-nitro-l-arginine-methyl ester (l-NAME) in LF-SED and HF-RUN grou

255 Inhibition of NOS with N(omega)-nitro-L-arginine-methyl ester (L-NAME) significantly increased c

256 the NO synthase (NOS) inhibitor N(G)-nitro-L-arginine-methyl ester (L-NAME), demonstrating the requir

257 ent of EC with NOS inhibitor, Nomega-nitro-L-arginine-methyl ester (L-NAME), significantly inhibited

258 Addition of N G-nitro-l-arginine-methyl ester (L-NAME, 5 mM) to the probe perfus

259 received daily i.p. injections of NG-nitro-L-arginine-methyl ester (L-NAME; 8 mg/kg) during both the

260 N omega-Nitro-L-arginine-methyl-ester (L-NAME) augmented the myogenic re

261 aboratory has demonstrated that N(G)-nitro-L-arginine-methyl-ester (L-NAME) mitigated cerebral ischem

262 Nomega-nitro-L-arginine-methyl-ester (L-NAME) or placebo was administer

263 ring antagonism of NO synthase (N(G)-nitro-L-arginine methyl ester [L-NAME]) for 7, 14, or 21 days.

264 e and during NO inhibition (N(omega)-nitro-l-arginine methyl ester [L-NAME]).

265 own that inhibitors of NOS (N(omega)-nitro-L-arginine methyl ester [L-NAME], 7-nitroindazole [7-NI])

266 Nomega-Nitro-L-arginine methyl ester, L-arginine, or adenosine was admi

267 : NO synthase inhibition (10 mM N(G)-nitro-L-arginine methyl ester, L-NAME); low-dose NO infusion (1.

268 (with L-arginine) or blocking (with nitro-L-arginine methyl ester, (L-NAME)) NO synthesis could modu

269 specific NOS inhibitor L-NAME (N(G)-nitro-l-arginine methyl ester) led to increased APP and BACE1 (b

270 (NO) synthase inhibitor l-NAME (N(G)-nitro-l-arginine methyl ester) markedly inhibited the vasodilati

271 ther, the inhibition of eNOS (l-N(G)-nitro-L-arginine methyl ester), Mas (A-779), and SIRT1 (nicotina

272 The eNOS inhibitor N(G)-Nitro-l-arginine methyl ester mimicked anti-VEGF/VEGFR drugs, ra

273 ic oxide (NO) synthase with N(omega)-l-nitro-arginine-methyl ester (n = 5) significantly elevated mea

274 e performed on solutions containing N-acetyl arginine methyl ester, N-acetyl lysine methyl ester, gua

275 e (protein kinase C inhibitor), N(G)-nitro-L-arginine methyl ester (nitric oxide synthase inhibitor),

276 L-NAME (N(omega)-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)

277 inhibitory effects of ADMA and N(G)-nitro-l-arginine methyl ester on inducible NOS (macrophages) and

278 ic-oxide synthase inhibitor N(omega)-nitro-L-arginine methyl ester or by the vanilloid VR1 receptor a

279 treatment of wild-type mice with NG-nitro-L-arginine methyl ester or loperamide prevented both the i

280 e nitric oxide synthase inhibitor N(omega)-L-arginine methyl ester or the xanthine oxidase inhibitor

281 ch was abolished by eNOS inhibitor N-nitro-L-arginine-methyl ester or H2O2 scavenger polyethylene gly

282 controls with NOS inhibited by N(G)-nitro-L-arginine methyl ester, or soluble guanylate cyclase (sGC

283 received 35 mg kg-1 day-1 of Nomega-nitro-L-arginine methyl ester orally for 10 days to inhibit NO s

284 de (NO) synthase inhibitor N(omega) -nitro-l-arginine methyl ester (P > 0.05), indicating that lower

285 Glibenclamide and N(G)-nitro-l-arginine methyl ester partially blocked the effect, indi

286 d that the small-molecule inhibitor, tosyl-l-arginine methyl ester, preferentially suppresses APC/C(C

287 h the NO synthase (NOS) inhibitor, N-nitro-l-arginine methyl ester prevented ischemia-induced AR acti

288 N(omega)-nitro-l-arginine methyl ester reduced vasodilation to flow in ad

289 Inhibition of NOS by N(G)-nitro-l-arginine-methyl ester restored the ability of endotoxin

290 ionylation and eNOS-derived N(omega)-nitro-L-arginine methyl ester-sensitive superoxide formation in

291 lial nitric oxide synthase with N(G)-nitro-L-arginine methyl ester significantly attenuated the high

292 in vessels from rats treated with N-nitro-L-arginine methyl ester to increase blood pressure.

293 Furthermore, N(omega)-nitro-L-arginine methyl ester-treated or eNOS-deficient female m

294 When low-dose chronic Nomega-nitro-L-arginine methyl ester treatment was added for WF A/I-tre

295 fluoro-2-phenyl-1H-indol-3-yl)-1-oxobutyl]-L-arginine methyl ester trifluoroacetate) in M1 ipRGCs.

296 However, inhibition of NOS by N(G)-nitro-L-arginine methyl ester was accompanied by a sparing of CD

297 e HR, the NO synthase inhibitor N(G)-nitro-L-arginine methyl ester was coinoculated with the avirulen

298 no further increases were seen when L-nitro-arginine-methyl ester was added.

299 -dansyl-N(omega)-(1,N(6)-etheno-ADP-ribosyl)-arginine methyl ester, was independent of redox potentia

300 or of nitric oxide synthesis L-NAME (L-nitro-arginine methyl ester), which had no effect of its own o